Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/5764
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Chan, TH | - |
dc.creator | Lam, WH | - |
dc.creator | Chow, LMC | - |
dc.creator | Dou, QP | - |
dc.creator | Kuhn, DJ | - |
dc.creator | Kazi, A | - |
dc.creator | Wan, SB | - |
dc.creator | Landis-Piwowar, KR | - |
dc.date.accessioned | 2013-05-29T04:20:36Z | - |
dc.date.available | 2013-05-29T04:20:36Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/5764 | - |
dc.language.iso | en | en_US |
dc.rights | Assignee: The Hong Kong Polytechnic University. | en_US |
dc.rights | Assignee: Wayne State University. | en_US |
dc.rights | Assignee: University of South Florida. | en_US |
dc.title | (-)-Epigallocatechin gallate derivatives for inhibiting proteasome | en_US |
dc.type | Patent | en_US |
dc.description.otherinformation | US8193377; US8193377 B2; US8193377B2; US8,193,377; US 8,193,377 B2; 8193377; Appl. No. 11/660,513 | en_US |
dc.description.otherinformation | Inventor name used in this publication: Larry Ming-Cheung Chow | en_US |
dc.description.otherinformation | Inventor name used in this publication: Qing Ping Dou | en_US |
dcterms.abstract | (-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃, and R₄ are each independently selected from the group consisting of --H, and C₁ to C₁₀ acyloxyl group; and R₅ is selected from the group consisting of --H, C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₃-C₇-cycloalkyl, phenyl, benzyl and C₃-C₇-cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃ and R₄ is --H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth. | - |
dcterms.bibliographicCitation | US Patent 8,193,377 B2. Washington, DC: US Patent and Trademark Office, 2012. | - |
dcterms.issued | 2012-06-05 | - |
dc.description.country | US | - |
dc.description.oa | Version of Record | en_US |
Appears in Collections: | Patent |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
us8193377b2.pdf | 2.06 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.